FrancophonIA/ELRC3.0 huggingface dataset:
English: MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS BLISTER / 30, 30x1, 50x1, 90x1 and 100x1 tablets
Croatian: PODACI KOJE MORA NAJMANJE SADRŽAVATI BLISTER ILI STRIP BLISTER / 30, 30x1, 50x1, 90x1 i 100x1 tableta
English: In patients concomitantly receiving nicorandil and NSAIDs including ASA and LAS, there is an increased risk for severe complications such as gastrointestinal ulceration, perforation and haemorrhage (see section 4.4).
Croatian: U bolesnika koji istodobno primaju nikorandil i NSAIL-ove uključujući ASK i LAS (lizinacetilsalicilna kiselina), povećan je rizik od teških komplikacija poput gastrointestinalne ulceracije, perforacije i hemoragije (vidjeti dio 4.4).
English: Acetylsalicylic acid (ASA):
Croatian: Acetilsalicilatna kiselina (ASK)
English: Bleeding time prolonged, neutrophil count decreased, platelet count decreased
Croatian: Pretrage produljeno vrijeme krvarenja, smanjeni broj neutrofila, smanjeni broj trombocita
English: The concomitant administration of DuoPlavin with oral anticoagulants is not recommended since it may increase the intensity of bleeding (see section 4.5).
Croatian: Ne preporučuje se istodobna primjena DuoPlavina i drugih oralnih antikoagulansa, jer to može pojačati intenzitet krvarenja (vidjeti dio 4.5.).
English: Jaundice (yellowing of skin and/or eyes); burning in stomach and/or esophagus (gullet); severe abdominal pain with or without back pain; fever, breathing difficulties sometimes associated with cough; generalised allergic reactions (for example, overall sensation of heat with sudden general discomfort until fainting); swelling in the mouth; blisters of the skin; skin allergy; sore mouth (stomatitis); decrease in blood pressure; confusion; hallucinations; joint pain; muscular pain; changes in taste or loss of taste of foods, inflammation of small vessels.
Croatian: Vrlo rijetke nuspojave (mogu se javiti u manje od 1 na 10 000 osoba): žutica (žuta boja kože i/ili očiju); žarenje u želucu i/ili jednjaku (ždrijelo); jaka bol u trbuhu s ili bez bolova u leđima; vrućica, teškoće pri disanju, ponekad povezane s kašljem, generalizirane alergijske reakcije (primjerice, opći osjećaj vrućine s iznenadnom općom nelagodom do nesvjestice); oticanje u ustima; mjehurići na koži; kožne alergijske reakcije; upala u usnoj šupljini (stomatitis); pad krvnoga tlaka; zbunjenost; halucinacije; bol u zglobovima; bol u mišićima; poremećaj okusa ili gubitak osjeta okusa hrane, upala malih krvnih žila.
English: Due to the presence of ASA, methotrexate used at doses higher than 20 mg/week should be used with caution with DuoPlavin as it can inhibit renal clearance of methotrexate, which may lead to bone marrow toxicity.
Croatian: Metotreksat primjenjen u dozi većoj od 20 mg tjedno, treba uzimati s oprezom, jer DuoPlavin, zbog ASK u svome sastavu, može smanjiti bubrežni klirens metotreksata, što može dovesti do toksičnih učinaka na koštanu srž.
English: Ulcer perforation, ringing in the ears, hearing loss, sudden life-threatening allergic or hypersensitivity reactions with chest or abdominal pain, kidney disease, low blood sugar, gout (a condition of painful, swollen joints caused by uric acid crystals) and worsening of food allergies, a particular form of anaemia (low number of red blood cells) (see section 2 ‘Warnings and precautions'), swelling.
Croatian: Nuspojave nepoznate učestalosti (učestalost se ne može procijeniti iz dostupnih podataka): perforacija (puknuće) čira, zujanje u ušima, gubitak sluha, iznenadne, po život opasne alergijske reakcije ili reakcije preosjetljivosti s boli u prsima ili abdomenu, bolest bubrega, niska razina šećera u krvi, giht (stanje bolnih, nateknutih zglobova uzrokovanih kristalima mokraćne kiseline) i pogoršanje alergije na hranu, određena vrsta anemije (nizak broj crvenih krvnih stanica) (vidjeti dio 2. "Upozorenja i mjere opreza"), oticanje.
English: Renal failure*, acute renal impairment (especially in patients with existing renal impairment, heart decompensation, nephritic syndrome, or concomitant treatment with diuretics)*, glomerulonephritis, blood creatinine increased
Croatian: Poremećaji bubrega i mokraćnog sustava hematurija zatajenje bubrega*, akutno oštećenje bubrežne funkcije (naročito u bolesnika s postojećim oštećenjem bubrega, srčanom dekompenzacijom, nefrotičkim sindromom, ili istovremenom terapijom diureticima)*, glomerulonefritis, povišenje kreatinina u krvi
English: Upper gastrointestinal disorders (oesophagitis, oesophageal ulceration, perforation, erosive gastritis, erosive duodenitis; gastro-duodenal ulcer/perforations)*; lower gastrointestinal disorders (small [jejunum and ileum] and large [colon and rectum] intestinal ulcers, colitis and intestinal perforation)*; upper gastro-intestinal symptoms* such as gastralgia (see section 4.4); these ASArelated GI reactions may or may not be associated with haemorrhage, and may occur at any dose of acetylsalicylic acid and in patients with or without warning symptoms or a previous history of serious GI events*.
Croatian: Poremećaji probavnog sustava gastrointestinalno krvarenje, proljev, bol u trbuhu, dispepsija ulkus želuca i dvanaesnika, gastritis, povraćanje, mučnina, konstipacija, flatulencija retroperitonealno krvarenje gastrointestinalna i retroperitonealna krvarenja sa smrtnim ishodom, pankreatitis, poremećaji u gornjem gastrointestinalnom traktu (ezofagitis, ezofagealna ulceracija, perforacija, erozivni gastritis, erozivni duodenitis; gastroduodenalni ulkus/perforacije)*; poremećaji u donjem gastrointestinalnom traktu (ulkusi tankog [jejunum i ileum] i debelog [kolon i rektum] crijeva, kolitis i perforacije crijeva)*; simptomi u gornjem gastrointestinalnom traktu*, npr. gastralgija (vidjeti dio 4.4.); ove gastrointestinalne reakcije povezane s ASK mogu ili ne moraju biti udružene s krvarenjem, i mogu se javiti pri bilo kojoj dozi acetilsalicilatne kiseline i u bolesnika s ili bez upozoravajućih simptoma ili ranijih ozbiljnih gastrointestinalnih događaja u povijesti bolesti*.
English: As a precaution concomitant use of strong or moderate CYP2C19 inhibitors should be discouraged (see sections 4.4 and 5.2).
Croatian: Kao mjera opreza, ne preporučuje se istodobna primjena lijekova koji su jaki ili umjereni inhibitori CYP2C19 (vidjeti dio 4.4. i 5.2.).
English: 14 film-coated tablets 28 film-coated tablets 30x1 film-coated tablet 50x1 film-coated tablet 84 film-coated tablets 90x1film-coated tablet 100x1 film-coated tablet
Croatian: 14 filmom obloženih tableta 28 filmom obloženih tableta 30x1 filmom obloženih tableta 50x1 filmom obloženih tableta 84 filmom obložene tablete 90x1filmom obloženih tableta 100x1 filmom obloženih tableta
English: Hypoglycaemia*, gout* (see section 4.4)
Croatian: Poremećaji metabolizma i prehrane hipoglikemija*, giht* (vidjeti dio 4.4.)
English: concomitant use of strong or moderate CYP2C19 inhibitors should be discouraged (see section 4.5 for a list of CYP2C19 inhibitors, see also section 5.2).
Croatian: Kao mjera opreza, ne preporučuje se istodobna primjena lijekova koji su jaki ili umjereni inhibitori CYP2C19 (za popis inhibitora CYP2C19 vidjeti dio 4.5., također vidjeti dio 5.2.).
English: The most common side effect which has been seen with DuoPlavin is bleeding.
Croatian: Najčešća nuspojava DuoPlavina jest krvarenje.
English: 14 film-coated tablets 28 film-coated tablets 30x1 film-coated tablet 50x1 film-coated tablet 84 film-coated tablets 90x1film-coated tablet 100x1 film-coated tablet 30 film-coated tablets
Croatian: 14 filmom obloženih tableta 28 filmom obloženih tableta 30x1 filmom obloženih tableta 50x1 filmom obloženih tableta 84 filmom obložene tablete 90x1filmom obloženih tableta 100x1 filmom obloženih tableta 30 filmom obloženih tableta
English: The other ingredients are: - Tablet core: mannitol (E421), macrogol 6000, microcrystalline cellulose, low substituted hydroxypropylcellulose, maize starch, hydrogenated castor oil (see section 2 ‘DuoPlavin contains hydrogenated castor oil'), stearic acid and colloidal anhydrous silica - Tablet coating: lactose monohydrate (see section 2 ‘DuoPlavin contains lactose'), hypromellose (E464), titanium dioxide (E171), triacetin (E1518), red iron oxide (E172) - Polishing agent: carnauba wax
Croatian: Drugi sastojci su: - Jezgra tablete: manitol (E421), makrogol 6000, mikrokristalična celuloza, nisko supstituirana hidroksipropilceluloza, kukuruzni škrob, hidrogenirano ricinusovo ulje (vidjeti dio 2. "DuoPlavin sadrži hidrogenirano ricinusovo ulje"), stearatna kiselina i koloidni, bezvodni silicijev dioksid - Ovojnica tablete: laktoza hidrat (vidjeti dio 2. "DuoPlavin sadrži laktozu"), hipromeloza (E464), titanijev dioksid (E171), triacetin (E1518), crveni željezov oksid (E172) - Sredstvo za poliranje: karnauba vosak
English: DuoPlavin is supplied in cardboard cartons containing: - 14, 28 and 84 tablets in all-aluminium blisters - 30x1, 50x1, 90x1 and 100x1 tablet in all-aluminium perforated unit-dose blisters.
Croatian: DuoPlavin je dostupan u kartonskim kutijama koje sadrže: - 14, 28 i 84 tablete u aluminijskim blisterima - 30x1, 50x1, 90x1 i 100x1 tableta u perforiranim aluminijskim blisterima s jediničnim dozama.
English: Bullous dermatitis (toxic epidermal necrolysis, Stevens Johnson Syndrome, erythema multiforme, acute generalised exanthematous pustulosis (AGEP)), angioedema, drug-induced hypersensitivity syndrome, drug rash with eosinophilia and systemic symptoms (DRESS), rash erythematous or exfoliative, urticaria, eczema, lichen planus, fixed eruption*
Croatian: bulozni dermatitis (toksična epidermalna nekroliza, Stevens Johnsonov sindrom, erythema multiforme, akutna generalizirana egzantematozna pustuloza (AGEP)), angioedem, sindrom preosjetljivosti izazvane lijekom, osip uzrokovan lijekom s eozinofilijom i sistemskim simptomima (engl.
English: DuoPlavin is supplied in cardboard cartons containing: - 14, 28, 30 and 84 tablets in all-aluminium blisters - 30x1, 50x1, 90x1 and 100x1 tablet in all-aluminium perforated unit-dose blisters.
Croatian: DuoPlavin je dostupan u kartonskim kutijama koje sadrže: - 14, 28, 30 i 84 tablete u aluminijskim blisterima - 30x1, 50x1, 90x1 i 100x1 tableta u perforiranim aluminijskim blisterima djeljivim na pojedinačne doze.
English: DuoPlavin must not be used in patients with severe hepatic impairment (see section 4.3).
Croatian: DuoPlavin se ne smije upotrebljavati u bolesnika s teškim oštećenjem funkcije jetre (vidjeti dio 4.3.).
English: Patients were required to have either ECG changes compatible with new ischaemia or elevated cardiac enzymes or troponin I or T to at least twice the upper limit of normal.
Croatian: Uključujći kriteriji su bili promjene u EKG-u povezane s novom ishemijom ili povećane vrijednosti srčanih enzima, ili troponin
English: DuoPlavin must not be used in patients with severe renal impairment (see section 4.3).
Croatian: DuoPlavin se ne smije upotrebljavati u bolesnika s teškim oštećenjem funkcije bubrega (vidjeti dio 4.3.).
English: Experimental data suggest that ibuprofen may inhibit the effect of low dose aspirin on platelet aggregation when they are dosed concomitantly.
Croatian: Eksperimentalni podaci upućuju da istovremeno primjenjeni ibuprofen inhibira učinak niske doze acetilsalicilatne kiseline na agregaciju trombocita.
English: - if you have any stomach or abdominal pain or bleeding in the stomach or bowels (red stools or black stools).
Croatian: • Obavijestite svog liječnika - ako planirate kirurški zahvat (uključujući stomatološke zahvate), - ako imate želučane ili abdominalne bolove ili krvaranje u želucu ili crijevima (crvena ili crna stolica).
English: Therapeutic experience is limited in patients with moderate hepatic disease who may have bleeding diatheses (see section 4.4).
Croatian: Terapijsko iskustvo u bolesnika s umjerenim oštećenjem funkcije jetre koji bi mogli imati povećanu sklonost krvarenju je ograničeno (vidjeti dio 4.4.).
English: Consequently, the concomitant use of NSAIDs including Cox-2 inhibitors is not recommended (see section 4.4).
Croatian: Stoga se ne preporučuje istodobna primjena klopidogrela i nesteroidnih protuupalnih lijekova, uključujući Cox-2 inhibitore (vidjeti dio
English: Therapeutic experience is limited in patients with mild to moderate renal impairment (see section 4.4).
Croatian: Terapijsko iskustvo u bolesnika s blagim do umjerenim oštećenjem funkcije bubrega je ograničeno (vidjeti dio 4.4.).
English: DuoPlavin 75 mg/75 mg film-coated tablets Aluminium blisters in cardboard cartons containing 14, 28, 30 and 84 film-coated tablets.
Croatian: DuoPlavin 75 mg/75 mg filmom obložene tablete 14, 28, 30 i 84 filmom obloženih tableta u aluminijskim blisterima, u kartonskoj kutiji.
English: - Tablet core: mannitol (E421), macrogol 6000, microcrystalline cellulose, low substituted hydroxypropylcellulose, maize starch, hydrogenated castor oil (see section 2 ‘DuoPlavin contains hydrogenated castor oil'), stearic acid and colloidal anhydrous silica - Tablet coating: lactose monohydrate (see section 2 ‘DuoPlavin contains lactose'), hypromellose (E464), titanium dioxide (E171), triacetin (E1518), yellow iron oxide (E172) - Polishing agent: carnauba wax
Croatian: Drugi sastojci su: - Jezgra tablete: manitol (E421), makrogol 6000, mikrokristalična celuloza, nisko supstituirana hidroksipropilceluloza, kukuruzni škrob, hidrogenirano ricinusovo ulje (vidjeti dio 2. "DuoPlavin sadrži hidrogenirano ricinusovo ulje"), stearatna kiselina i koloidni, bezvodni silicijev dioksid - Ovojnica tablete: laktoza hidrat (vidjeti dio 2. "DuoPlavin sadrži laktozu"), hipromeloza (E464), titanijev dioksid (E171), triacetin (E1518), žuti željezov oksid (E172) - Sredstvo za poliranje: karnauba vosak
English: The number of patients experiencing the co-primary endpoint (CV death, MI, stroke or refractory ischaemia) was 1,035 (16.5%) in the clopidogrel plus ASA group and 1,187 (18.8%) in the ASA group, a 14% relative risk reduction (95% CI of 6%-21%, p=0.0005) for the clopidogrel plus ASA group.
Croatian: U skupini koja je primala klopidogrel plus ASK bilo je 1035 (16,5%) bolesnika sa koprimarnim ishodom (smrt zbog kardiovaskularnih uzroka, infarkt miokarda, moždani udar ili refraktorna ishemija), odnosno 1187 (18,8%) bolesnika u skupini koja je primala samo ASK, što znači smanjenje relativnoga rizika od 14% (95% CI: 6%-21%, p=0,0005) u skupini koja je primala klopidogrel plus ASK.
English: DuoPlavin has no or negligible influence on the ability to drive and use machines.
Croatian: 4.7 Utjecaj na sposobnost upravljanja vozilima i rada sa strojevima DuoPlavin ne utječe ili zanemarivo utječe na sposobnost upravljanja vozilima i rada sa strojevima.
English: The ASA in DuoPlavin is rapidly hydrolyzed in plasma to salicylic acid, with a half-life of 0.3 to 0.4 hours for ASA doses from 75 to 100 mg. Salicylic acid is primarily conjugated in the liver to form salicyluric acid, a phenolic glucuronide, an acyl glucuronide, and a number of minor metabolites.
Croatian: ASK iz DuoPlavina brzo se u plazmi hidrolizira u salicilatnu kiselinu koja ima poluvijek od 0,3-0,4 sata za doze ASK od 75 do 100 mg.
English: Respiratory tract bleeding (haemoptysis, pulmonary haemorrhage), bronchospasm, interstitial pneumonitis, non-cardiogenic pulmonary edema with chronic use and in the context of a hypersensitivity reaction due to acetylsalicylic acid*, eosinophilic pneumonia.
Croatian: Poremećaji dišnog sustava, prsišta i sredoprsja epistaksa krvarenje u dišnome sustavu (hemoptiza, plućno krvarenje), bronhospazam, intersticijski pneumonitis, nekardiogeni edem pluća pri kroničnoj primjeni i u sklopu reakcije preosjetljivosti na acetilsalicilatnu kiselinu*, eozinofilna pneumonija
English: • swelling in the mouth or skin disorders such as rashes and itching, blisters of the skin.
Croatian: • oticanje u ustima ili kožne poremećaje kao što su osip i svrbež te mjehurići na koži; ovi simptomi mogu biti znakovi alergijske reakcije.
English: Clopidogrel must be metabolised by CYP450 enzymes to produce the active metabolite that inhibits platelet aggregation.
Croatian: Da bi nastao taj aktivni metabolit, klopidogrel se mora metabolizirati pomoću enzima CYP450.
English: Thrombotic thrombocytopenic purpura (TTP) (see section 4.4), bone marrow failure*, aplastic anaemia, pancytopenia, bicytopenia*, agranulocytosis, severe thrombocytopenia, acquired haemophilia A, granulocytopenia, anaemia, haemolytic anaemia in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency* (see section 4.4)
Croatian: Poremećaji krvi i limfnog sustava trombocitopenija, leukopenija, eozinofilija neutropenija, uključujući tešku neutropeniju trombotična trombocitopenična purpura (TTP) (vidjeti dio 4.4.), zatajenje koštane srži*, aplastična anemija, pancitopenija, bicitopenija*, agranulocitoza, teška trombocitopenija, stečena hemofilija A, granulocitopenija, anemija, hemolitička anemija u bolesnika s nedostatkom glukoza-6fosfat dehidrogenaze (G6PD)* (vidjeti dio
English: DuoPlavin 75 mg/75 mg film-coated tablets (tablets) are oval, slightly biconvex, yellow, engraved on one side with ‘C75' and ‘A75'on the other side.
Croatian: DuoPlavin 75 mg/75 mg filmom obložene tablete (tablete) su ovalne, blago bikonveksne, žute tablete s utisnutom oznakom "C75" na jednoj i "A75" na drugoj strani.
English: DuoPlavin 75 mg/75 mg film-coated tablets DuoPlavin should be given as a single daily 75 mg/75 mg dose.
Croatian: DuoPlavin 75mg/75 mg filmom obložene tablete DuoPlavin se daje u jednokratnoj dnevnoj dozi od 75 mg/75 mg.
English: You should stop other clopidogrel treatment while you are taking DuoPlavin.
Croatian: Dok uzimate DuoPlavin, trebate prekinuti drugu terapiju klopidogrelom.
English: DuoPlavin 75 mg/100 mg film-coated tablets DuoPlavin should be given as a single daily 75 mg/100 mg dose.
Croatian: DuoPlavin 75mg/100 mg filmom obložene tablete DuoPlavin se daje u jednokratnoj dnevnoj dozi od 75 mg/100 mg.
English: EU/1/10/619/008 14 film-coated tablets EU/1/10/619/009 28 film-coated tablets EU/1/10/619/010 30x1 film-coated tablet EU/1/10/619/011 50x1 film-coated tablet EU/1/10/619/012 84 film-coated tablets EU/1/10/619/013 90x1 film-coated tablet EU/1/10/619/014 100x1 film-coated tablet
Croatian: EU/1/10/619/008 14 filmom obloženih tableta EU/1/10/619/009 28 filmom obloženih tableta EU/1/10/619/010 30x1 filmom obloženih tableta EU/1/10/619/011 50x1 filmom obloženih tableta EU/1/10/619/012 84 filmom obloženih tableta EU/1/10/619/013 90x1 filmom obloženih tableta EU/1/10/619/014 100x1 filmom obloženih tableta
English: DuoPlavin 75 mg/75 mg film-coated tablets EU/1/10/619/001 - Cartons of 14 film-coated tablets in aluminium blister packs EU/1/10/619/002 - Cartons of 28 film-coated tablets in aluminium blister packs EU/1/10/619/003 - Cartons of 30x1 film-coated tablet in aluminium blister packs EU/1/10/619/004 - Cartons of 50x1 film-coated tablet in aluminium blister packs EU/1/10/619/005 - Cartons of 84 film-coated tablets in aluminium blister packs EU/1/10/619/006 - Cartons of 90x1film-coated tablet in aluminium blister packs EU/1/10/619/007 - Cartons of 100x1film-coated tablet in aluminium blister packs EU/1/10/619/015 - Cartons of 30 film-coated tablet in aluminium blister packs
Croatian: DuoPlavin 75 mg/75 mg filmom obložene tablete EU/1/10/619/001 - kutije s 14 filmom obloženih tableta u aluminijskim blisterima EU/1/10/619/002 - kutije s 28 filmom obloženih tableta u aluminijskim blisterima EU/1/10/619/003 - kutije s 30x1 filmom obloženih tableta u aluminijskim blisterima EU/1/10/619/004 - kutije s 50x1 filmom obloženih tableta u aluminijskim blisterima EU/1/10/619/005 - kutije s 84 filmom obložene tablete u aluminijskim blisterima EU/1/10/619/006 - kutije s 90x1 filmom obloženih tableta u aluminijskim blisterima EU/1/10/619/007 - kutije sa 100x1 filmom obloženih tableta u aluminijskim blisterima EU/1/10/619/015 - kutije s 30 filmom obloženih tableta u aluminijskim blisterima
English: DuoPlavin 75 mg/75 mg film-coated tablets DuoPlavin 75 mg/100 mg film-coated tablets
Croatian: DuoPlavin 75 mg/75 mg filmom obložene tablete DuoPlavin 75 mg/100 mg filmom obložene tablete
English: EU/1/10/619/001 14 film-coated tablets EU/1/10/619/002 28 film-coated tablets EU/1/10/619/003 30x1 film-coated tablet EU/1/10/619/004 50x1 film-coated tablet EU/1/10/619/005 84 film-coated tablets EU/1/10/619/006 90x1 film-coated tablet EU/1/10/619/007 100x1 film-coated tablet EU/1/10/619/015 30 film-coated tablets
Croatian: EU/1/10/619/001 14 filmom obloženih tableta EU/1/10/619/002 28 filmom obloženih tableta EU/1/10/619/003 30x1 filmom obloženih tableta EU/1/10/619/004 50x1 filmom obloženih tableta EU/1/10/619/005 84 filmom obloženih tableta EU/1/10/619/006 90x1 filmom obloženih tableta EU/1/10/619/007 100x1 filmom obloženih tableta EU/1/10/619/015 30 filmom obloženih tableta
English: DuoPlavin 75 mg/100 mg film-coated tablets (tablets) are oval, slightly biconvex, light pink, engraved on one side with ‘C75' and ‘A100'on the other side.
Croatian: DuoPlavin 75 mg/100 mg filmom obložene tablete Svijetloružičaste, ovalne, blago bikonveksne tablete, s utisnutim oznakama "C75" na jednoj i "A100" na drugoj strani.
English: DuoPlavin 75 mg/100 mg film-coated tablets EU/1/10/619/008 - Cartons of 14 film-coated tablets in aluminium blister packs EU/1/10/619/009 - Cartons of 28 film-coated tablets in aluminium blister packs EU/1/10/619/010 - Cartons of 30x1 film-coated tablet in aluminium blister packs EU/1/10/619/011 - Cartons of 50x1 film-coated tablet in aluminium blister packs EU/1/10/619/012 - Cartons of 84 film-coated tablets in aluminium blister packs EU/1/10/619/013 - Cartons of 90x1 film-coated tablet in aluminium blister packs EU/1/10/619/014 - Cartons of 100x1 film-coated tablet in aluminium blister packs
Croatian: DuoPlavin 75 mg/100 mg filmom obložene tablete EU/1/10/619/008 - kutije s 14 filmom obloženih tableta u aluminijskim blisterima EU/1/10/619/009 - kutije s 28 filmom obloženih tableta u aluminijskim blisterima EU/1/10/619/010 - kutije s 30x1 filmom obloženih tableta u aluminijskim blisterima EU/1/10/619/011 - kutije s 50x1 filmom obloženih tableta u aluminijskim blisterima EU/1/10/619/012 - kutije s 84 filmom obložene tablete u aluminijskim blisterima EU/1/10/619/013 - kutije s 90x1 filmom obloženih tableta u aluminijskim blisterima EU/1/10/619/014 - kutije sa 100x1 filmom obloženih tableta u aluminijskim blisterima
English: DuoPlavin 75 mg/75 mg film-coated tablets DuoPlavin 75 mg/100 mg film-coated tablets clopidogrel/acetylsalicylic acid
Croatian: DuoPlavin 75 mg/75 mg filmom obložene tablete DuoPlavin 75 mg/100 mg filmom obložene tablete klopidogrel/acetilsalicilatna kiselina
English: DuoPlavin 75 mg/75 mg film-coated tablets
Croatian: DuoPlavin 75 mg/75 mg filmom obložene tablete
English: DuoPlavin 75 mg/100 mg film-coated tablets
Croatian: DuoPlavin 75 mg/100 mg filmom obložene tablete
English: If you take more DuoPlavin than you should
Croatian: Dok uzimate DuoPlavin, ne biste smjeli dojiti.
English: Hydrogenated castor oil Stearic acid
Croatian: DuoPlavin sadrži hidrogenirano ricinusovo ulje
English: Gynaecomastia
Croatian: Nikorandil
English: Each tablet contains: 75 mg of clopidogrel (as hydrogen sulphate) and 100 mg of acetylsalicylic acid.
Croatian: Jedna tableta sadrži: 75 mg klopidogrela (u obliku klopidogrelhidrogensulfata) i 100 mg acetilsalicilatne kiseline.
English: Each tablet contains: 75 mg of clopidogrel (as hydrogen sulphate) and 75 mg of acetylsalicylic acid.
Croatian: Jedna tableta sadržava: 75 mg klopidogrela (u obliku klopidogrelhidrogensulfata) i 75 mg acetilsalicilatne kiseline.
English: Each tablet contains 75 mg of clopidogrel (as hydrogen sulphate) and 75 mg of acetylsalicylic acid.
Croatian: Jedna tableta sadržava 75 mg klopidogrela (u obliku klopidogrelhidrogensulfata) i 75 mg acetilsalicilatne kiseline.
English: • paclitaxel, medicine to treat cancer,
Croatian: o oralne antikoagulanse, lijekove koji sprječavaju zgrušavanje krvi,
English: DuoPlavin 75 mg/100 mg film-coated tablets clopidogrel/acetylsalicylic acid
Croatian: DuoPlavin 75 mg/100 mg filmom obložene tablete klopidogrel/acetilsalicilatna kiselina
English: Each tablet contains 75 mg of clopidogrel (as hydrogen sulphate) and 100 mg of acetylsalicylic acid.
Croatian: Jedna tableta sadržava 75 mg klopidogrela (u obliku klopidogrelhidrogensulfata) i 100 mg acetilsalicilatne kiseline.